Mesenchymal stem cell-derived neural progenitors in progressive MS: Two-year follow-up of a phase I study
Conclusions
Safety and efficacy of repeated IT-MSC-NP treatment was sustained for 2 years; however, the degree of disability reversal was not sustained in a subset of patients. CSF biomarkers altered in response to IT-MSC-NP treatment may reflect specific immunoregulatory and trophic mechanisms of therapeutic response in MS.
Classification of evidence
This study provides Class IV evidence that for patients with progressive MS, IT administration of MSC-NPs is safe and effective. The study is rated Class IV because of the absence of a non–IT-MSC-NP-treated control group.
Clinicaltrials.gov identifier
NCT01933802.
Source: Neurology Neuroimmunology and Neuroinflammation - Category: Neurology Authors: Harris, V. K., Stark, J. W., Yang, S., Zanker, S., Tuddenham, J., Sadiq, S. A. Tags: All Clinical trials, Multiple sclerosis Article Source Type: research
More News: Brain | Clinical Trials | Disability | Multiple Sclerosis | Neurology | Stem Cell Therapy | Stem Cells | Study